@RWinayak @montypal
Very impressive results here #ASCO26
Interested in the assumptions/stats behind the planned phase 3 trial. Given the effect in the phase 2 seems so profound why does the sample size need to be so big in the phase 3 (n=750)
Are you going for OS?
Very impressive results here #ASCO26
Interested in the assumptions/stats behind the planned phase 3 trial. Given the effect in the phase 2 seems so profound why does the sample size need to be so big in the phase 3 (n=750)
Are you going for OS?
Superb presentation by @RWinayak mentee of the amazing @montypal
on microbial dysbiosis as predictor of benefit of microbiome CBM588 when added to ICI in RCC. #ASCO26 @ASCO
Very promising clinical outcomes laying the foundation of the ph 3 BIOFRONT trial led by @PBarataMD @SWOG
Kudos to @montypal for opening the frontier of Microbiome's to enhance ICI efficacy in RCC.View quoted post on X
